Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The task of the invention is therefore making available transfer capsules that are taken up by the target cell type and permanently or transiently modify the target cell, without exerting any toxic effects on the cell during this process. The solution according to the invention consists of the use of monodisperse cores, so as to produce polyelectrolyte nanocapsules having cell-specific sizes from them. The sizes for hematopoietic cells are in a range of 20-80 nm, preferably in a range of 40-60 nm. In this regard, the sizes of the particles must be in a very narrow range, so as to prevent toxic effects from occurring. In order to keep the toxicity of the nanocapsules low, it is furthermore important to remove the nanoparticles around which the capsules are built up (cores) before use. Methods in this regard are known from the state of the art (for example dissolution by means of EDTA). A further task is the stabilization of the transfer capsules.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present invention relates to an in vitro process for the diagnosis of prostate cancer and other tumor types in exosomes obtained from a body fluid which comprises a) concentrating the exosomes and other extracellular vesicles from a body fluid of a patient, b) extraction of total RNA from the exosomes obtained in step a), c) conversion of the RNA obtained in step b) to cDNA, d) amplification of the cDNA obtained in step c) with a polymerase chain reaction whereby primers derived from the AGR2 nucleotide sequence or the complement thereof are used, and e) determining whether in the amplification product variants of the AGR2 gene can be identified.

Abstract: The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.

Abstract: The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.

Abstract: Provided are nucleic acids capable of hybridizing to HPV 16 and/or HPV 18 nucleic acids, in particular, mRNA encoding E2 and E6-7 gene products. Such nucleic acids are useful in methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, methods and means for predicting the progression of precancerous cervical lesions, and methods and means for detecting disruption of genes or gene expression.

Abstract: Provided are methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, and methods and means for predicting the progression of precancerous cervical lesions.

Abstract: The present disclosure relates to immobilization of a cell using a carboxylated surface by contacting the carboxylated surface with a sample comprising the cell for a sufficient time to permit the cell to bind to the carboxylated surface. The immobilized cell may then be separated from the remainder of the sample and further manipulated to isolate, concentrate, and/or analyze the cell or a component thereof.

Abstract: Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step using two separate sequence-specific polynucleotide probes. Also provided are nucleic acids comprising SEQ ID NO: 1 to SEQ ID NO: 727 and nucleic acid probes and probe sets comprising the same.

Abstract: Methods are provided for genotyping a target nucleic acid in a sample. In various aspects, the methods comprise generating nucleic acid hybrids between probes specific for the genotypes of interest and the target nucleic acid and detecting hybridization in the sample. In other aspects, the methods comprise using multi-probe mixtures to reduce the volume of sample necessary to determine the genotype of the target nucleic acid.

Abstract: Disclosed are compositions and methods for random amplification of nucleic acid sequences of interest using random-G-deficient primers. Also disclosed are methods of randomly amplifying a target nucleic acid sequence using random G-deficient primers alone or in combination with random, partially random, or specific primers.

Abstract: The present invention relates to an in vitro process for the diagnosis of prostate cancer and other tumor types in exosomes obtained from a body fluid which comprises a) concentrating the exosomes and other extracellular vesicles from a body fluid of a patient, b) extraction of total RNA from the exosomes obtained in step a), c) conversion of the RNA obtained in step b) to cDNA, d) amplification of the cDNA obtained in step c) with a polymerase chain reaction whereby primers derived from the AGR2 nucleotide sequence or the complement thereof are used, and e) determining whether in the amplification product variants of the AGR2 gene can be identified.

Abstract: Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step comprising contacting the target nucleic acid with a plurality of detectably labeled nucleic acid detection probes, wherein each (a) bears a different detectable label from the other detection probes, and/or (b) has a different melting temperature from probes bearing the same detectable label. Also disclosed are compositions and kits for use in such a method.

Abstract: The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.

Abstract: Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods.

Abstract: Disclosed herein are methods of amplifying a target nucleic acid in a helicase-dependent reaction. Also disclosed are methods of amplifying and detecting a target nucleic acid in a helicase-dependent reaction as well as modified detection labels to assist in the detection.

Abstract: The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR.